Literature DB >> 18841469

The effects of endomorphins on striatal [3H]GABA release induced by electrical stimulation: an in vitro superfusion study in rats.

Zsolt Bagosi1, Miklós Jászberényi, Gyula Telegdy.   

Abstract

The endomorphins (EM1 and EM2) are selective endogenous ligands for mu-opioid receptors (MOR1 and MOR2) with neurotransmitter and neuromodulator roles in mammals. In the present study we investigated the potential actions of EMs on striatal GABA release and the implication of different MORs in these processes. Rat striatal slices were preincubated with tritium-labelled GABA ([(3)H]GABA), pretreated with selective MOR1 and MOR2 antagonist beta-funaltrexamine and selective MOR1 antagonist naloxonazine and then superfused with the selective MOR agonists, EM1 and EM2. EM1 significantly decreased the striatal [(3)H]GABA release induced by electrical stimulation. Beta-funaltrexamine antagonized the inhibitory action of EM1, but naloxonazine did not affect it considerably. EM2 was ineffective, even in case of specific enzyme inhibitor diprotin A pretreatment. The results demonstrate that EM1 decreases GABA release in the basal ganglia through MOR2, while EM2 does not influence it.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18841469     DOI: 10.1007/s11064-008-9853-z

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  16 in total

1.  Proteolysis of endomorphin-1 by brain synaptic membrane-associated peptidases.

Authors:  Liming Wu; Junhui Chen; Dulai Zhong; Chentao Lin; Xingchang Wang
Journal:  Acta Neurobiol Exp (Wars)       Date:  2002       Impact factor: 1.579

Review 2.  The endomorphin system and its evolving neurophysiological role.

Authors:  Jakub Fichna; Anna Janecka; Jean Costentin; Jean-Claude Do Rego
Journal:  Pharmacol Rev       Date:  2007-03       Impact factor: 25.468

3.  The effects of endomorphins and diprotin A on striatal dopamine release induced by electrical stimulation-an in vitro superfusion study in rats.

Authors:  Zsolt Bagosi; Miklós Jászberényi; Erika Bujdosó; Gyula Szabó; Gyula Telegdy
Journal:  Neurochem Int       Date:  2006-07-03       Impact factor: 3.921

4.  Differential distribution of endomorphin 1- and endomorphin 2-like immunoreactivities in the CNS of the rodent.

Authors:  S Martin-Schild; A A Gerall; A J Kastin; J E Zadina
Journal:  J Comp Neurol       Date:  1999-03-22       Impact factor: 3.215

Review 5.  Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Authors:  R Mentlein
Journal:  Regul Pept       Date:  1999-11-30

6.  Effects of endomorphin-1 on open-field behavior and on the hypothalamic-pituitary-adrenal system.

Authors:  E Bujdosó; M Jászberényi; C Tömböly; G Tóth; G Telegdy
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

7.  Diprotin A, an inhibitor of dipeptidyl aminopeptidase IV(EC 3.4.14.5) produces naloxone-reversible analgesia in rats.

Authors:  A Z Rónai; J Timár; E Makó; F Erdö; Z Gyarmati; G Tóth; G Orosz; S Fürst; J I Székely
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

8.  Role of GABAA receptors in the endomorphin-1-, but not endomorphin-2-, induced dopamine efflux in the nucleus accumbens of freely moving rats.

Authors:  Yuri Aono; Tadashi Saigusa; Naoko Mizoguchi; Tomoyo Iwakami; Koji Takada; Nobuhito Gionhaku; Yoshiyuki Oi; Koichiro Ueda; Noriaki Koshikawa; Alexander R Cools
Journal:  Eur J Pharmacol       Date:  2007-10-25       Impact factor: 4.432

9.  The effects of corticoptropin-releasing factor and the urocortins on striatal dopamine release induced by electrical stimulation-an in vitro superfusion study.

Authors:  Zsolt Bagosi; Miklós Jászberényi; Erika Bujdosó; Gyula Telegdy
Journal:  Neurochem Res       Date:  2006-03-02       Impact factor: 3.996

10.  Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study.

Authors:  Chikai Sakurada; Shinobu Sakurada; Takafumi Hayashi; Sou Katsuyama; Koichi Tan-No; Tsukasa Sakurada
Journal:  Biochem Pharmacol       Date:  2003-08-15       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.